Episealer®: Clinical results with 5-years’ follow-up data to be presented at the 3rd World Arthroplasty Congress
Episurf Medical (Nasdaq: EPIS B) today announces that the scientific report "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years” by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. The congress is arranged as a digital meeting on April 22-24, 2021. The presentation will be included in the ePosters Knee Session and focuses on clinical results from the use of the Episealer® knee implant.
“This is a great milestone for us as a company. For the first time ever, clinical results with 5-years’ follow-up of Episealer® patients are included in the scientific program at a major clinical congress. The investigator has informed us that the results are highly promising. Being able to demonstrate successful 5-years’ data is a critical milestone for any medtech company, but absolutely nothing one should take for granted. As previously communicated, another Episealer® knee study with promising 5 years’ follow-up data has been submitted for publication. I cannot emphasize enough the importance of all of this,” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags: